In the same vein, Lilly's Mounjaro is approved by the FDA for diabetes ... against Novo in weight loss while simultaneously ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...

Breen对Eli Lilly给予“跑赢大盘”的评级，并设定了1100美元的目标价，这意味着从周三收盘价来看，股价有38.2%的上涨潜力。Eli Lilly目前在糖尿病药物Mounjaro和减肥药物Zepbound等领域处于领先地位。

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...

药企正扩展其潜力 ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...